RecruitingNot applicableNCT05443087
TARGETed Therapy Drug MONITOring in DIGestive Oncology
Studying Combined hepatocellular carcinoma and cholangiocarcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- UNICANCER
- Principal Investigator
- David MALKA, DrGustave ROUSSY - VILLEJUIF
- Intervention
- Blood sampling to build population pharmacokinetics model(other)
- Enrollment
- 330 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2027
Study locations (29)
- CHU d'Amiens Pcardie - Hopital Sud, Amiens, France
- CH d'Auxerre, Auxerre, France
- Institut du Cancer Avignon - Institut Sainte Catherine, Avignon, France
- CH de Bayeux - Onconormandie, Bayeux, France
- Centre Jean Perrin, Clermont-Ferrand, France
- Hôpital Beaujon APHP, Clichy, France
- Centre Georges Francois Leclerc, Dijon, France
- Institut de Cancérologie de Bourgogne, Dijon, France
- CH Eure Seine - Hopital d'Evreux Vernon, Évreux, France
- Centre Oscar Lambret, Lille, France
- Groupement des hôpitaux de l'Institut Catholique de Lille - Hôpital Saint Vincent de Paul, Lille, France
- Centre Léon Bérard, Lyon, France
- Hôpital Européen Marseille, Marseille, France
- CHRU de Nancy - Hôpital de Brabois Adulte, Nancy, France
- CHU de Nantes - Hôtel Dieu, Nantes, France
- +14 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05443087 on ClinicalTrials.govOther trials for Combined hepatocellular carcinoma and cholangiocarcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06902246Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular CarcinomaUniversity of Miami
- RECRUITINGPHASE1NCT07419841A Phase 1 Study of the Safety and Tolerability of CTX-10726Compass Therapeutics
- RECRUITINGPHASE1NCT07493044An Open-Label, Phase I Clinical Trial of Super CAR-T With GPC3-Positive Advanced Hepatocellular CarcinomaGuangzhou FineImmune Biotechnology Co., LTD.
- RECRUITINGPHASE2NCT07122089Evaluation of SIRT Followed by Immunotherapy for Treatment of Hepatocellular Carcinoma With Portal Vein ThrombosisCenter Eugene Marquis
- RECRUITINGPHASE1, PHASE2NCT07482059A Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular CarcinomaWest China Hospital
- RECRUITINGPHASE2NCT06254248Safety of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced Hepatocellular CarcinomaAssistance Publique - Hôpitaux de Paris
- RECRUITINGNANCT07469319Biannual Screening for HCC Offered to Patients With Cirrhosis. Introducing Surveillance for Hepatocellular Carcinoma (HCC) in the Central Denmark Region Using Ultrasound and Alpha-Fetoprotein to Reduce HCC-Related Mortality in Patients With Compensated Non-Viral CirrhosisUniversity of Aarhus
- RECRUITINGEARLY PHASE1NCT07242417TC-G203 for Patients With GPC3-Positive Advanced Solid TumorsBeijing GoBroad Hospital
See all trials for Combined hepatocellular carcinoma and cholangiocarcinoma →